These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 16352595)
1. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. Proia DA; Nannenga BW; Donehower LA; Weigel NL J Biol Chem; 2006 Mar; 281(11):7089-101. PubMed ID: 16352595 [TBL] [Abstract][Full Text] [Related]
2. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785 [TBL] [Abstract][Full Text] [Related]
3. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D. Lu X; Nguyen TA; Donehower LA Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689 [TBL] [Abstract][Full Text] [Related]
4. PP2Cdelta (Ppm1d, WIP1), an endogenous inhibitor of p38 MAPK, is regulated along with Trp53 and Cdkn2a following p38 MAPK inhibition during mouse preimplantation development. Hickson JA; Fong B; Watson PH; Watson AJ Mol Reprod Dev; 2007 Jul; 74(7):821-34. PubMed ID: 17219434 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of the wip1 gene abrogates the p38 MAPK/p53/Wip1 pathway and silences p16 expression in human breast cancers. Yu E; Ahn YS; Jang SJ; Kim MJ; Yoon HS; Gong G; Choi J Breast Cancer Res Treat; 2007 Mar; 101(3):269-78. PubMed ID: 16897432 [TBL] [Abstract][Full Text] [Related]
6. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice. Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371 [TBL] [Abstract][Full Text] [Related]
7. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. Wu W; Pew T; Zou M; Pang D; Conzen SD J Biol Chem; 2005 Feb; 280(6):4117-24. PubMed ID: 15590693 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Chen L; Mayer JA; Krisko TI; Speers CW; Wang T; Hilsenbeck SG; Brown PH Cancer Res; 2009 Dec; 69(23):8853-61. PubMed ID: 19920204 [TBL] [Abstract][Full Text] [Related]
9. PPM1D phosphatase, a target of p53 and RBM38 RNA-binding protein, inhibits p53 mRNA translation via dephosphorylation of RBM38. Zhang M; Xu E; Zhang J; Chen X Oncogene; 2015 Nov; 34(48):5900-11. PubMed ID: 25823026 [TBL] [Abstract][Full Text] [Related]
11. Silencing of PPM1D inhibits cell proliferation and invasion through the p38 MAPK and p53 signaling pathway in papillary thyroid carcinoma. Lu ZW; Wen D; Wei WJ; Han LT; Xiang J; Wang YL; Wang Y; Liao T; Ji QH Oncol Rep; 2020 Mar; 43(3):783-794. PubMed ID: 31922231 [TBL] [Abstract][Full Text] [Related]
12. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. Kishi H; Nakagawa K; Matsumoto M; Suga M; Ando M; Taya Y; Yamaizumi M J Biol Chem; 2001 Oct; 276(42):39115-22. PubMed ID: 11495913 [TBL] [Abstract][Full Text] [Related]
13. Identification of differentially expressed genes after PPM1D silencing in breast cancer. Pärssinen J; Alarmo EL; Khan S; Karhu R; Vihinen M; Kallioniemi A Cancer Lett; 2008 Jan; 259(1):61-70. PubMed ID: 17977650 [TBL] [Abstract][Full Text] [Related]
14. PPM1D Knockdown Suppresses Cell Proliferation, Promotes Cell Apoptosis, and Activates p38 MAPK/p53 Signaling Pathway in Acute Myeloid Leukemia. Li B; Hu J; He D; Chen Q; Liu S; Zhu X; Yu M Technol Cancer Res Treat; 2020; 19():1533033820942312. PubMed ID: 32691668 [TBL] [Abstract][Full Text] [Related]
15. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas. Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255 [TBL] [Abstract][Full Text] [Related]
16. Characterization of the active site and a unique uncompetitive inhibitor of the PPM1-type protein phosphatase PPM1D. Chuman Y; Yagi H; Fukuda T; Nomura T; Matsukizono M; Shimohigashi Y; Sakaguchi K Protein Pept Lett; 2008; 15(9):938-48. PubMed ID: 18991770 [TBL] [Abstract][Full Text] [Related]
17. The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Rauta J; Alarmo EL; Kauraniemi P; Karhu R; Kuukasjärvi T; Kallioniemi A Breast Cancer Res Treat; 2006 Feb; 95(3):257-63. PubMed ID: 16254685 [TBL] [Abstract][Full Text] [Related]
18. PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms. Wu B; Guo BM; Kang J; Deng XZ; Fan YB; Zhang XP; Ai KX Apoptosis; 2016 Mar; 21(3):365-78. PubMed ID: 26714478 [TBL] [Abstract][Full Text] [Related]
19. The estrogen receptor alpha pathway induces oncogenic Wip1 phosphatase gene expression. Han HS; Yu E; Song JY; Park JY; Jang SJ; Choi J Mol Cancer Res; 2009 May; 7(5):713-23. PubMed ID: 19435816 [TBL] [Abstract][Full Text] [Related]